Form 4 for TLSI TriSalus Life Sciences, Inc.

Accepted 2026-05-18 16:42:30 ET · period of report 2026-05-15 · accession 0001628280-26-035994 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-05-18 16:42	2026-05-15	TLSI	Szela Mary T	CEO, Pres, Dir	P - Purchase	$2.59	+39.7K	1.07M	+4%	+$102.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-05-15	P	A	39,682	$2.59	1,065,215	D	—	—	(F1) The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85. The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person. The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction. (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.